Additional expression of T-cell engager in clinically tested oncolytic adeno-immunotherapy redirects tumor-infiltrated, irrelevant T cells against cancer cells to enhance antitumor immunity
Our results indicate that CAdTetra effectively induces adaptive T-cell responses against cancer cells by using tumor-infiltrating irrelevant T cells.
Authors
- Spyridoula Vasileiou (ORCID: https://orcid.org/0000-0002-7970-9391)
- Amanda Rosewell Shaw (ORCID: https://orcid.org/0000-0002-9642-3926)
- Daisuke Morita (ORCID: https://orcid.org/0000-0002-7476-7285)
- Bora Lim (ORCID: https://orcid.org/0000-0002-4182-6058)
- Greyson Biegert (ORCID: https://orcid.org/0000-0003-1413-6630)
- Masataka Suzuki (ORCID: https://orcid.org/0000-0003-4086-4199)
- Caroline E. Porter (ORCID: https://orcid.org/0000-0002-8500-2608)
- Mae Woods (ORCID: https://orcid.org/0000-0002-4155-8524)
Institutions
- Houston Methodist (US)
- The University of Texas MD Anderson Cancer Center (US)
- Shinshu University (JP)
- Baylor College of Medicine (US)
- Benedict College (US)
- Methodist Hospital (US)
- Texas Children's Hospital (US)
Publication Details
- Journal
- Journal for ImmunoTherapy of Cancer
- Published
- 2024-12-01
- DOI
- https://doi.org/10.1136/jitc-2024-009741
- Citations
- 5
- Primary Topic
- Virus-based gene therapy research
- Type
- article
- Field-Weighted Citation Impact
- 2.75
Funders
- Naito Foundation
- National Institutes of Health
- National Heart, Lung, and Blood Institute
- National Cancer Institute